Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Allergy Therapeutics ( (GB:AGY) ).
Allergy Therapeutics has announced a rectification of an administrative oversight related to the exercise of options under the company’s block admission facility. An application has been made for 709,638 ordinary shares to be admitted to trading on AIM, with trading expected to commence on or around 27 December 2024. This action does not affect the total issued share capital of the company, which remains at 4,766,439,938 ordinary shares. The announcement is expected to maintain shareholder transparency and ensure compliance with disclosure obligations.
More about Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company based in the UK, specializing in the treatment and diagnosis of allergic disorders. The company focuses on developing aluminium-free immunotherapies and distributes proprietary and third-party products across nine major European countries and through agreements in an additional ten countries.
YTD Price Performance: 156.00%
Average Trading Volume: 429,664
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £305.1M
See more data about AGY stock on TipRanks’ Stock Analysis page.
